Speciality: Oncology
Description:
A warm welcome to all the medical professionals joining us for this insightful session on the multifaceted advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies. The landscape of advanced breast cancer treatment has been profoundly reshaped by the advent of CDK4/6 inhibitors. These targeted therapies, including palbociclib, ribociclib, and abemaciclib, have revolutionized the management of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, demonstrating significant improvements in progression-free and overall survival rates compared to traditional endocrine therapy alone. Their mechanism of action, by selectively inhibiting cyclin-dependent kinases 4 and 6, effectively halts cell cycle progression and offers a more precise approach to combating cancer.
Dr. Bhavna Parikh, a distinguished expert in the field, will delve into the compelling clinical evidence supporting the widespread adoption of these agents. Through landmark clinical trials, CDK4/6 inhibitors have consistently shown superior efficacy, extending the time patients live without disease progression and enhancing their quality of life. This session will explore the nuances of these studies, highlighting the patient populations who benefit most, the optimal sequencing strategies, and the management of potential side effects, ensuring a comprehensive understanding of their practical application in clinical settings.
The integration of CDK4/6 inhibitors into the treatment paradigm for HR+/HER2- advanced breast cancer represents a monumental leap forward in personalized oncology. This webinar is an invaluable opportunity to gain an overall knowledge of the best practices and latest advancements in leveraging these inhibitors for improved patient outcomes. Don't miss this chance to grab the shared knowledge and follow Hidoc for more such interesting webinar sessions that keep you at the forefront of medical innovation.
See More Webinars @ Hidoc Webinars
1.
U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain
2.
Prostate cancer screening seems to be improved by PSA, biomarker testing, and MRI combined.
3.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
4.
A large study found that monolayers were superior in detecting cancer.
5.
New drug combination shows particularly good results in patients with HPV-negative head and neck cancer
1.
Chondroma: What it is and How it Affects Your Health
2.
The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy
3.
Know About Lymphangioma: Symptoms, Causes, and Treatments
4.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
5.
Breaking Barriers in Cancer Treatment: The Role of Innovative Oncology Drugs
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
3.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation